These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24752310)

  • 1. Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct?
    Payne PW
    Pharmacogenomics J; 2014 Oct; 14(5):473-80. PubMed ID: 24752310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. For Asians only? The perils of ancestry-based drug prescribing.
    Payne PW
    J Law Med Ethics; 2008; 36(3):585-8. PubMed ID: 18840252
    [No Abstract]   [Full Text] [Related]  

  • 3. Race and Pharmacogenomics-Personalized Medicine or Misguided Practice?
    Goodman CW; Brett AS
    JAMA; 2021 Feb; 325(7):625-626. PubMed ID: 33492362
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States.
    Choi H; Mohit B
    Epilepsia; 2019 Jul; 60(7):1472-1481. PubMed ID: 31158306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment.
    Tan JC; Murrell DF; Hersch MI
    J Clin Neurosci; 2015 Dec; 22(12):1992-3. PubMed ID: 26319500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between HLA-B*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study.
    Kwan PK; Ng MH; Lo SV
    Hong Kong Med J; 2014 Dec; 20 Suppl 7():16-8. PubMed ID: 25647819
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: HLA B*1502 allele association with oxcarbamazepine-induced skin reactions in epilepsy patient from India.
    Shankarkumar U; Shah KN; Ghosh K
    Epilepsia; 2009 Jul; 50(7):1837-8. PubMed ID: 20831525
    [No Abstract]   [Full Text] [Related]  

  • 8. HLA-B*1502 haplotype screening prior to carbamazepine administration in individuals of south-east Asian ancestry nears cost-effectiveness in preventing severe cutaneous adverse drug reactions.
    Kim E; McCrossin I; Frew JW
    Australas J Dermatol; 2018 Aug; 59(3):245-246. PubMed ID: 29226308
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular identification of HLA-B75 serotype markers by qPCR: A more inclusive pharmacogenetic approach before carbamazepine prescription.
    Jaruthamsophon K; Sangmanee P; Plong-On O; Charalsawadi C; Sukasem C; Hnoonual A
    Clin Transl Sci; 2024 Jun; 17(6):e13867. PubMed ID: 38894615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal trends and patterns in carbamazepine use, related severe cutaneous adverse reactions, and HLA-B*15:02 screening: A nationwide study.
    Lin CW; Huang WI; Chao PH; Chen WW; Hsiao FY
    Epilepsia; 2018 Dec; 59(12):2325-2339. PubMed ID: 30479027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Stevens-Johnson syndrome/toxic epidermal necrolysis after initiation of carbamazepine in a HLA-B*15:02 gene carrier – screening in risk patients is recommended].
    Anastasopoulou S; Komuda M; Presman B; Karlsson M; Tomson T
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28221394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications.
    Lo C; Nguyen S; Yang C; Witt L; Wen A; Liao TV; Nguyen J; Lin B; Altman RB; Palaniappan L
    Clin Transl Sci; 2020 Sep; 13(5):861-870. PubMed ID: 32100936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in genetic studies on severe cutaneous adverse reactions to anti-epileptic drugs].
    He XL; Liu ZS
    Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):906-8. PubMed ID: 23324146
    [No Abstract]   [Full Text] [Related]  

  • 14. A marker for Stevens-Johnson syndrome ...: ethnicity matters.
    Lonjou C; Thomas L; Borot N; Ledger N; de Toma C; LeLouet H; Graf E; Schumacher M; Hovnanian A; Mockenhaupt M; Roujeau JC;
    Pharmacogenomics J; 2006; 6(4):265-8. PubMed ID: 16415921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-B*1502 screening and toxic effects of carbamazepine.
    Phillips EJ; Mallal SA
    N Engl J Med; 2011 Aug; 365(7):672; author reply 673. PubMed ID: 21848472
    [No Abstract]   [Full Text] [Related]  

  • 16. HLA-B*1502 screening and toxic effects of carbamazepine.
    Liao WP; Shi YW; Min FL
    N Engl J Med; 2011 Aug; 365(7):672-3; author reply 673. PubMed ID: 21848471
    [No Abstract]   [Full Text] [Related]  

  • 17. A study of HLA-B*15:02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS/TEN.
    Ou GJ; Wang J; Ji X; Yu H; Jiang L; Li L; Chen Q; Su PC; Liu Z
    HLA; 2017 Apr; 89(4):225-229. PubMed ID: 28205426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions.
    Locharernkul C; Shotelersuk V; Hirankarn N
    J Clin Neurosci; 2011 Oct; 18(10):1289-94. PubMed ID: 21802305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.
    Chong KW; Chan DW; Cheung YB; Ching LK; Hie SL; Thomas T; Ling S; Tan EC
    Arch Dis Child; 2014 Jun; 99(6):581-4. PubMed ID: 24225276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions.
    Nguyen DV; Vidal C; Chi HC; Do NTQ; Fulton R; Li J; Fernando SL
    HLA; 2017 Dec; 90(6):335-342. PubMed ID: 28884973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.